Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administration

British Journal of Pharmacology

Volumn 170, Issue 2, 2013, Pages 440-457

  Chen, Feng ^a,b,c   Li, Li ^a   Xu, Fang ^a   Sun, Yan ^a   Du, Feifei ^a   Ma, Xutao ^a   Zhong, Chenchun ^a   Li, Xiuxue ^a   Wang, Fengqing ^a   Zhang, Nating ^a   Li, Chuan ^a,b,d  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c HAINAN MEDICAL UNIVERSITY   (China)

^d INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

cerebral exposure; flavonols; GBE50; Ginkgo biloba; pharmacokinetics; PK markers; route of administration; ShuXueNing injection; systemic exposure; terpene lactones

Indexed keywords

BILOBALIDE; FLAVANOL DERIVATIVE; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE J; ISORHAMNETIN; ISORHAMNETIN 3 O DIRHAMNOSYL GLUCOSIDE; ISORHAMNETIN 3 O GLUCOSYL O RHAMNOSIDE; ISORHAMNETIN 3 O RHAMNOSYL O GLUCOSIDE; KAEMPFEROL; KAEMPFEROL 3 O (4 COUMAROYL)GLUCOSYL O RHAMNOSIDE; KAEMPFEROL 3 O DIRHAMNOSYL GLUCOSIDE; KAEMPFEROL 3 O GLUCOSYL O RHAMNOSIDE; KAEMPFEROL 3 O RHAMNOSYL O GLUCOSIDE; QUERCETIN; QUERCETIN 3 O (4 COUMAROYL)GLUCOSYL O RHAMNOSIDE; QUERCETIN 3 O DIRHAMNOSYL GLUCOSIDE; QUERCETIN 3 O GLUCOSYL O RHAMNOSIDE; QUERCETIN 3 O RHAMNOSYL O GLUCOSIDE; TERPENE DERIVATIVE; TERPENE LACTONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYSTEMIC EXPOSUE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ENTEROHEPATIC CIRCULATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICRODIALYSIS; NONHUMAN; PLANT LEAF; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT;

CEREBRAL EXPOSURE; FLAVONOLS; GBE50; GINKGO BILOBA; PHARMACOKINETICS; PK MARKERS; ROUTE OF ADMINISTRATION; SHUXUENING INJECTION; SYSTEMIC EXPOSURE; TERPENE LACTONES;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CHROMATOGRAPHY, LIQUID; DRUGS, CHINESE HERBAL; FLAVONOLS; GINKGO BILOBA; GLYCOSIDES; LACTONES; MALE; MASS SPECTROMETRY; MICRODIALYSIS; PLANT EXTRACTS; PLANT LEAVES; RATS; RATS, SPRAGUE-DAWLEY; TERPENES; TISSUE DISTRIBUTION;

EID: 84883255312     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12285     Document Type: Article

References (53)

1. Bhattaram VA, Graefe U, Kohlert C, Veit M, Derendorf H, (2002). Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 9 (Suppl. 3): 1-33.
2. Biber A, (2003). Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 36 (Suppl. 1): S32-S37.
3. Cashman JR, Ghirmai S, Abel KJ, Fiala M, (2008). Immune defects in Alzheimer's disease: new medications development. BMC Neurosci 9 (Suppl. 2): S13.
4. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck M-P, et al. (2007). Modeling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 6: 650-661.
5. Chen JS, Huang PH, Wang CH, Lin FY, Tsai HY, Wu TC, et al. (2011). Nrf-2 mediated heme oxygenase-1 expression, an antioxidant-independent mechanism, contributes to anti-atherogenesis and vascular protective effects of Ginkgo biloba extract. Atherosclerosis 214: 301-309.
6. Chen JW, Chen YH, Lin FY, Chen YL, Lin SJ, (2003). Ginkgo biloba extract inhibits tumor necrosis factor-induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells. Arterioscler Thromb Vasc Biol 23: 1559-1566.
7. Chen Z-P, Sun J, Chen H-X, Xiao Y-Y, Liu D, Chen J, et al. (2010). Comparative pharmacokinetics and bioavailability studies of quercetin, kaempferol and isorhamnetin after oral administration of Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes and Ginkgo biloba extract solid dispersions in rats. Fitoterapia 81: 1045-1052.
8. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, et al. (1999). Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56: 1135-1140.
9. Darvesh AS, Carroll RT, Bishayee A, Novotny NA, Geldenhuys WJ, Van de Schyf CJ, (2012). Curcumin and neurodegenerative diseases: a perspective. Expert Opin Investig Drugs 21: 1123-1140.
10. Davies B, Morris T, (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095.
11. DeFeudis FV, Drieu K, (2000). In vitro studies of the pharmacological and biochemical activities of Ginkgo biloba extract (EGb761) and its constituents. In:, van Beek TA, (ed.). Ginkgo Biloba. Harwood Academic Publishers: Amsterdam, pp. 279-301.
12. Drieu K, DeFeudis FV, (2000). In vivo studies of the pharmacological and biochemical activities of Ginkgo biloba Extract (EGb761) and its constituents. In:, van Beek TA, (ed.). Ginkgo Biloba. Harwood Academic Publishers: Amsterdam, pp. 303-329.
13. Fagerholm U, (2008). The role of permeability in drug ADME/PK, interactions and toxicity-presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans. Pharm Res 25: 625-638.
14. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH, (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
15. Guo B, Li C, Wang G-J, Chen L-S, (2006). Rapid and direct measurement of free concentrations of highly protein-bound fluoxetine and its metabolite norfluoxetine in plasma. Rapid Commun Mass Spectrom 20: 39-47.
16. Hu Z-Y, Yang J-L, Cheng C, Huang Y-H, Du F-F, Wang F-Q, et al. (2013). Combinatorial metabolism notably affects human systemic exposure to ginsenosides from orally administered extract of Panax notoginseng roots (Sanqi). Drug Metab Dispos 41: 1457-1469.
17. Huang SY, Jeng C, Kao SC, Yu JJH, Liu DZ, (2004). Improved haemorrheological properties by ginkgo biloba extract (Egb761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr 23: 615-621.
18. Ishizawa K, Yoshizumi M, Kawai Y, Terao J, Kihira Y, Ikeda Y, et al. (2011). Pharmacology in health food: metabolism of quercetin in vivo and its protective effect against arteriosclerosis. J Pharmacol Sci 115: 466-470.
19. A receptors. J Biol Chem 278: 49279-49285.
20. Kleijnen J, Knipschild P, (1992). Ginkgo biloba. Lancet 340: 1136-1139.
21. Koltermann A, Hartkorn A, Koch E, Furst R, Vollmar AM, Zahler S, (2007). Ginkgo biloba extract EGb761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci 64: 1715-1722.
22. Lang D, Ude C, Wurglics M, Schubert-Zsilavecz M, Klein J, (2010). Brain permeability of bilobalide as probed by microdialysis before and after middle cerebral artery occlusion in mice. J Pharm Pharm Sci 13: 607-614.
23. Li C, (2012). Absorption, disposition, and pharmacokinetics of herbal medicines: what and how? Curr Drug Metab 13: 491-493.
24. Li L, Zhao Y-S, Du F-F, Yang J-L, Xu F, Niu W, et al. (2012). Intestinal absorption and presystemic elimination of various chemical constituents present in GBE50 extract, a standardized extract of Ginkgo biloba leaves. Curr Drug Metab 13: 494-509.
25. Liu H-F, Yang J-L, Du F-F, Gao X-M, Ma X-T, Huang Y-H, et al. (2009). Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos 37: 2290-2298.
26. Lodi F, Jimenez R, Moreno L, Kroon PA, Needs PW, Hughes DA, et al. (2009). Glucuronidated and sulfated metabolites of the flavonoid quercetin prevent endothelial dysfunction but lack direct vasorelaxant effects in rat aorta. Atherosclerosis 204: 34-39.
27. Longpré F, Garneau P, Christen Y, Ramassamy C, (2006). Protection by Egb761 against β-amyloid-induced neurotoxicity: involvement of NF-κB, SIRT1, and MAPKs pathways and inhibiton of amyloid fibril formation. Free Radic Biol Med 41: 1781-1794.
28. Lu T, Yang J-L, Gao X-M, Chen P, Du F-F, Sun Y, et al. (2008). Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen), can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine. Drug Metab Dispos 36: 1578-1586.
29. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, et al. (2002). Inhibition of amyoid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A 99: 12197-12202.
30. Mashayekh A, Pham DL, Yousem DM, Dizon M, Barker PB, Lin DDM, (2011). Effects of Ginkgo biloba on cerebral blood flow assessed by quantitative MR perfusion imaging: a pilot study. Neuroradiology 53: 185-191.
31. Ou HC, Lee WJ, Lee IT, Chiu TH, Tsai KL, Lin CY, et al. (2009). Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol 106: 1674-1685.
32. Perez-Vizcaino F, Duarte J, (2010). Flavonols and cardiovascular disease. Mol Aspects Med 31: 478-494.
33. Rangel-Ordõñez L, Nöldner M, Schubert-Zsilavecz M, Wurglics M, (2010). Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb761. Planta Med 76: 1683-1690.
34. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M, (2002). Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41: 751-790.
35. Rossi R, Basillco F, Rossoni G, Riva A, Morazzoni P, Mauri PL, (2009). Liquid chromagraphy/atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex. J Pharm Biomed Anal 50: 224-227.
36. Saleem S, Zhuang H, Biswal S, Christen Y, Doré S, (2008). Ginkgo biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury. Stroke 39: 3389-3396.
37. Shi C, Wu F, Yew DT, Xu J, Zhu Y, (2010). Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Apoptosis 15: 715-727.
38. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. (2000). Confidence interval criteria for assessment of dose proportionality. Pharm Res 17: 1278-1283.
39. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW, (2008). The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 363: 1-25.
40. Storkebaum E, Quaegebeur A, Vikkula M, Carmeliet P, (2011). Cerebrovascular disorders: molecular insights and therapeutic opportunities. Nat Neurosci 14: 1390-1397.
41. 2 receptors, in rats. Br J Pharmacol 158: 1302-1312.
42. Suri S, Liu XH, Rayment S, Hughes DA, Kroon PA, Needs PW, et al. (2010). Quercetin and its major metabolites selectively modulate cyclic GMP-dependent relaxations and associated tolerance in pig isolated coronary artery. Br J Pharmacol 159: 566-575.
43. Tchantchou F, Xu Y, Wu YJ, Christen Y, Luo Y, (2007). EGb761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. FASEB J 21: 2400-2408.
44. Tchantchou F, Lacor PN, Cao Z, Lao L, Hou Y, Cui C, et al. (2009). Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J Alzheimers Dis 18: 787-798.
45. Tribolo S, Lodi F, Connor C, Suri S, Wilson VG, Taylor MA, et al. (2008). Comparative effects of quercetin and its predominant human metabolites on adhesion molecule expression in activated human vascular endothelial cells. Atherosclerosis 197: 50-56.
46. Tsai JY, Su KH, Shyue SK, Kou YR, Yu YB, Hsiao SH, et al. (2010). EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res 88: 415-423.
47. Vida C, De la Fuente M, (2013). Chapter 8 Stress-related Behavioural Responses, Immunity and Ageing in Animal Models. In:, Bosch JA, Phillips AC, Lord JM, (eds). Immunosenescence: Psychosocial and Behavioral Determinans. Springer: New York, pp. 125-144.
48. Watson GS, Baker LD, Cholerton BA, Rhoads KW, Merriam GR, Schellenberg GD, et al. (2009). Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease. J Alzheimers Dis 18: 595-602.
49. Wu Y-Z, Li S-Q, Cui W, Zu X-G, Wang F-F, Du J, (2007). Ginkgo biloba extract improves coronary blood flow in patients with coronary artery disease: role of endothelial-dependent vasodilation. Planta Med 73: 624-628.
50. Yoshitake T, Yoshitake S, Kehr J, (2010). The Ginkgo biloba extract EGb761 and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol 159: 659-668.
51. Zhao Y, Sun Y, Li C, (2008). Simultaneous determination of ginkgo flavonoids and terpenoids in plasma: ammonium formate in LC mobile phase enhancing electrospray ionization efficiency and capacity. J Am Soc Mass Spectrom 19: 445-449.
52. Zhou L, Meng Q-J, Qian T, Yang Z-Q, (2011). Ginkgo biloba extract enhances glucose tolerance in hyperinsulinism-induced hepatic cells. J Nat Med 65: 50-56.
53. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q-Z, Chen C-Y, (2004). Clinical use and molecular mechanisms of action of extract of Ginkgo biloba leaves in cardiovascular diseases. Cardiovasc Drug Rev 22: 309-319.